June 2026 in “Indian Dermatology Online Journal” In this pilot study, both tofacitinib and methotrexate improved alopecia areata outcomes, but tofacitinib showed greater efficacy in achieving significant SALT score improvement after 6 months, although the difference was not statistically significant.
June 2026 in “Lasers in Medical Science” This randomized trial found that diode laser achieved more favorable long-term hair removal outcomes but induced more discomfort and transient adverse effects compared to intense pulsed light in women with Fitzpatrick skin types I-IV.
May 2026 in “Journal of the American Academy of Dermatology” In this study, sublingual minoxidil was found to be a safe and effective treatment for increasing hair growth in transgender individuals with mild androgenetic alopecia who are undergoing full-dose testosterone therapy.
This source reports that in adults with non-scarring alopecia, polyphenolic interventions significantly improved hair density and total area hair count compared to controls, although considerable variability was present in results, highlighting the need for further research.
This systematic review and meta-analysis found that polyphenolic interventions significantly improved hair density and total area hair count in adults with non-scarring alopecia, but substantial heterogeneity was observed.
This study evaluated the efficacy of polyphenolic compounds for hair growth in adults with non-scarring alopecia and found that these interventions significantly improved hair density and total area hair count compared to controls, although results were not significantly different from minoxidil.
In a phase 2 trial, researchers tested a topical formulation for alopecia areata and found significant hair regrowth with the treatment, but these improvements did not lead to substantial enhancements in health-related quality of life.
In this phase 2 trial, STS01 1% significantly improved hair regrowth in patients with mild to moderate patchy alopecia areata compared to placebo, with a manageable skin irritation side effect profile.
March 2026 in “SKIN The Journal of Cutaneous Medicine” This study found that ritlecitinib was well tolerated in children aged 6 to under 12 years with severe alopecia areata, with ongoing trials examining its efficacy and safety over a 24-week period and in long-term use up to 36 months.
March 2026 in “Journal of Cosmetic Dermatology” Keratinocyte Growth Factor-Hair Serum may help prevent hair loss during chemotherapy, but more research is needed.
January 2026 in “The FASEB Journal” This upcoming clinical trial at Shenzhen People's Hospital will explore the safety and efficacy of human umbilical cord mesenchymal stem cell-derived small extracellular vesicles as a treatment for androgenetic alopecia in young men, comparing them to minoxidil. Results are not reported yet.
January 2026 in “Journal of Ayurveda and Integrated Medical Sciences” In this study, oral Bhringaraj extract was found to significantly reduce hair shedding in adults over 24 weeks, according to comb test measurements and patient-reported improvements, with mild and self-resolving side effects observed.
January 2026 in “Dermatologica Sinica” In this study, oral minoxidil (1.25 mg and 2.5 mg) and topical 5% minoxidil significantly promoted hair regrowth in men with androgenetic alopecia over six months, showing comparable efficacy across both oral and topical treatments.
January 2026 in “British Journal of Dermatology” This study found that combined microneedling with minoxidil significantly improved hair count and diameter in patients with androgenetic alopecia compared to minoxidil alone, despite mild adverse events, and microneedling parameters like depth and duration did not significantly affect outcomes.
November 2025 in “Frontiers in Nutrition” Olive leaf extract may help reduce aging signs in postmenopausal women.
November 2025 in “SKIN The Journal of Cutaneous Medicine” This study evaluated the long-term safety of ritlecitinib in adolescents with alopecia areata and found it to be well-tolerated without new safety concerns over approximately five years, with common adverse events including positive SARS-CoV-2 tests, acne, headache, and nasopharyngitis.
November 2025 in “SKIN The Journal of Cutaneous Medicine” In this phase 3 trial, baricitinib showed effectiveness and safety in both adolescents and adults with severe alopecia areata, with adolescents achieving higher response rates despite more severe baseline conditions, suggesting the advantages of early treatment.
November 2025 in “Journal of Multidisciplinary Healthcare” This study found that combining fire needle therapy with DHT treatment over eight weeks improved lesion severity, scar symptoms, quality of life, and reduced serum inflammatory cytokine levels in patients with moderate-to-severe acne vulgaris compared to using DHT alone.
October 2025 in “Plastic & Reconstructive Surgery” This study evaluated the safety and effectiveness of MNC-QQ cell therapy in five men with androgenic alopecia, reporting no adverse effects and improvements in hair growth, hair density, and quality of life over six months.
October 2025 in “Dermatology and Therapy” This study evaluates the efficacy and safety of a higher dose (100-mg) of ritlecitinib for treating severe alopecia areata, comparing it to external and synthetic placebo control groups.
September 2025 in “Journal of Pakistan Association of Dermatologists” This study compared the effectiveness of adding Biotin supplements to PRP treatment against using PRP alone for androgenetic alopecia patients and found no additional benefits in hair regrowth when Biotin was included.
September 2025 in “Journal of the American Academy of Dermatology” Combining minoxidil and PRP is more effective for hair growth than using either alone.
September 2025 in “Journal of the American Academy of Dermatology” Deuruxolitinib significantly improves hair satisfaction in severe alopecia areata patients.
August 2025 in “Lasers in Medical Science” In this study, the combination of low-level laser therapy and topical minoxidil was found to improve hair density and diameter more effectively than minoxidil alone in treating androgenic alopecia, with similar safety profiles observed in both groups.
This study concluded that adding a topical agent to intense pulsed light therapy significantly improved hair reduction and patient satisfaction in Pakistani women with idiopathic facial hirsutism compared to light therapy alone, without increasing adverse effects.
August 2025 in “Indian Dermatology Online Journal” This study found that combining topical minoxidil with phototherapy significantly improved pigmentation and reduced vitiligo severity compared to placebo, as measured by VASI scores over 12 weeks, though the sample size was small and follow-up short.
August 2025 in “BMJ Open” In this randomized controlled trial, researchers are assessing the efficacy and safety of acupoint catgut embedding combined with topical 5% minoxidil in treating androgenetic alopecia among 70 men, with primary outcomes focusing on changes in hair count after 24 weeks of treatment.
July 2025 in “Journal of Cosmetic Dermatology” In this clinical study involving individuals with localized alopecia areata, TrA injections were found to significantly outperform MTX, leading to better hair regrowth and higher patient satisfaction, though both treatments had similar mild side effects.
June 2025 in “Naunyn-Schmiedeberg s Archives of Pharmacology” This literature review reports that certain herbal remedies, such as rosemary, green tea, and ginseng, have shown promise in promoting hair growth and improving hair density, though variability and study design limitations highlight the need for more rigorous research.
In this clinical trial, rosemary-lavender and rosemary-castor oils were found to significantly improve hair growth rate, thickness, density, length, and reduce hair fall compared to coconut oil over 90 days, indicating they may be effective natural alternatives for hair regrowth.